ACC: Pericardial Effusion Prevalent in Hospitalized COVID-19 Patients
Prevalence of pericardial effusion in hospitalized COVID-19 patients is about 14 percent, but it rarely is attributable to pericarditis
FRIDAY, March 25, 2022 (HealthDay News) -- Pericardial effusion is prevalent among hospitalized patients with COVID-19, but is rarely due to pericarditis, according to a study published online March 21 in the Journal of the American Heart Association, ahead of presentation at the annual meeting of the American College of Cardiology, held from April 2 to 4 in Washington, D.C.
Eihab Ghantous, M.D., M.P.H., from the Tel Aviv Sourasky Medical Center in Israel, and colleagues examined the prevalence, associations, and clinical impact of pericardial involvement in 530 hospitalized patients with COVID-19.
The researchers found that 75 patients (14 percent) had pericardial effusion, but only 17 patients (3.2 percent) met the criteria for acute pericarditis. Independent associations were seen for pericardial effusion with modified early warning score, brain natriuretic peptide, and right ventricular function. In nonadjusted analysis, pericardial effusion was associated with excess mortality (hazard ratio, 2.44; 95 percent confidence interval, 1.50 to 3.83; P = 0.0005). After adjustment for modified early warning score and echocardiographic and hemodynamic parameters, there was a statistically nonsignificant association with mortality (hazard ratio, 1.86; 95 percent confidence interval, 0.95 to 3.5; P = 0.06) and improvement in the model fit. Assessment of pericardial effusion combined with modified early warning score, left ventricular ejection fraction (LVEF), and tricuspid annular plane systolic excursion (TAPSE) independently predicted outcome (hazard ratio, 1.86; 95 percent confidence interval, 1.09 to 3.07; P = 0.02) and improved model fit.
"To achieve significant clinical value for risk stratification, a limited echocardiographic examination, including LVEF, TAPSE, and evaluation for presence of pericardial effusion, is sufficient," the authors write.
The study was funded by Novartis Israel Ltd.